Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Depreciation and Depletion (2025)

VYNE Therapeutics (VYNE) has disclosed Depreciation and Depletion for 1 consecutive years, with $6000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Depreciation and Depletion changed N/A year-over-year to $6000.0, compared with a TTM value of $12000.0 through Jun 2025, changed N/A, and an annual FY2025 reading of $23000.0, up 475.0% over the prior year.
  • Depreciation and Depletion was $6000.0 for Q2 2025 at VYNE Therapeutics, roughly flat from $6000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $6000.0 in Q1 2025 and bottomed at $6000.0 in Q1 2025.